NEW YORK (GenomeWeb News) – Protagen said today that it has formed a collaboration with OncoTyrol to conduct validation studies on the firm's UniArray technology platform.

The study aims to determine the "most robust combination of putative prostate cancer markers and optimizing the diagnostic protein biochip to proceed to clinical trials," Protagen CEO Stefan Müllner said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.